First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00537901

Enrollment

100

Registered

2007-10-02

Start date

2007-10-31

Completion date

2013-10-31

Last updated

2015-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic Neoplasms, Rectal Neoplasms

Keywords

Colon and Rectum Cancer

Brief summary

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum

Interventions

RADIATIONFirst-Line Bevacizumab and Chemotherapy

Chemotherapy

DRUGBevacizumab

Chemotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with metastatic cancer of colon or rectum

Design outcomes

Primary

Measure	Time frame
Effectiveness	overall

Secondary

Measure	Time frame
Quality of life	overall

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026